Ilex Clolar Advisory Committee Splits On Pediatric Leukemia Approvals
Executive Summary
FDA's Oncologic Drugs Advisory Committee recommended accelerated approval for Ilex' Clolar (clofarabine) in the treatment of pediatric acute lymphoblastic leukemia, but not pediatric acute myelogenous leukemia, at its Dec. 1 meeting
You may also be interested in...
The Greatest FDA Advisory Committees, Part II: The Birth Of The ‘Pazdur Moment’
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
Clolar Launching For Pediatric ALL; Genzyme, FDA Discussing Adult Studies
Genzyme will employ a sales force of less than 10 to launch Clolar for pediatric acute lymphoblastic leukemia in January
Clolar Launching For Pediatric ALL; Genzyme, FDA Discussing Adult Studies
Genzyme will employ a sales force of less than 10 to launch Clolar for pediatric acute lymphoblastic leukemia in January